Xconomy | Boston - Business + Technology in the Exponential Economy

Related Posts

Biotech, Life Sciences, Vertex

Vertex To Sell 7 Million Shares of Stock

Luke Timmerman 9/17/08

Vertex Pharmaceuticals, the developer of telaprevir for hepatitis C, said today it is planning to sell 7 million new shares of stock. Goldman, Sachs & Co. is serving as the sole book-runner for the offering. Cambridge, MA-based Vertex (NASDAQ: VRTX) closed at $26.57 yesterday, down 5.6 percent on the day. The company had $832 million in cash and investments on hand at the end of June.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share:   Retweet Facebook Email

Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    
Xconomy network map Seattle Boston San Diego
national life-sciences startups

Most Popular Stories

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.